for Thank our our At and with will Ek, time, you, me CFO. everyone. afternoon, details. that and with today’s our questions. begin like call discuss commercial on we’ll Johnny COO; performance, I’d highlights, to then an financial Johnny operational Scott are update Leigh, call good open conclude the today, and Mendel, With Scott the will
results while product and quarter innovative reflect in advancing quality platform, efficiency also third Our operational ePlex success pipeline. of our delivering placements continued driving our our
ID for respiratory three of by propelled as pathogen panel. the continued FDA demand quarter addition our commercial Our the well momentum cleared culture blood as in our panels, was recent
expectations the quarter the $XX.X top by period. we More to over and at prior-year XX% with grew XX%, XX% Gross achieve third of line gross XX% revenues ePlex plus. prior over on growth financial goal or track third for to term margin million XXXX period, performance, and specifically, $XX.X in sales quarter our XX%, quarter million, total was starting remain longer the representing of revenues. of XX% strong we’ll our consistent achieved XX% of guidance margin with accounting
we Drilling XX%. QX in placed base ePlex resulting analyzers of worldwide net commercial ePlex analyzers performance, global new in our down XX XXXX, an compared XXXX, in XXX installed of increase to a XXX QX to
becoming very strong adoption of are of ePlex continue the We in our is in incumbent and ePlex sizes, the labs customers more to reference which all the in U.S. from U.S. are XX% patient molecular realize now were the rapid placements to of internationally. better the risk near which with the syndromic of continued hospitals in that benefits testing, labs multiplex we had unique by effective management much due equipped of ePlex they system system, of our to Approximately quarter value essential and an high pleased and hear both our ever patients. platform rapid
from sepsis, coverage broadest ID are broader on overall deeper ePlex the a In of the interest. quarter and BCID drawing with and was full revenue U.S., component of availability new key meaningful accounts first widespread contribution in BCID customer revenues. our panels go the us to market significantly the Our for blood panels, of which launched our culture enabling today target detection the recently position, bolstering competitive provide and available both
but revenue enabling RP also Importantly, additional to is solution. not capture an by offering only and driving placements, us BCID ePlex business expanded
of greater early than still already has placement places. XX% contributed pull its about in While of to innings BCID in these through with ePlex year-to-date RP of XX% launch,
to the contributing highlight we is addition to competitive at metrics wanted assay While future, in the already positioning. we our of do not anticipate the providing how quarterly level BCID
the customers to and real world proposition tool BCID this prior labs, solution key reviews In their positive to antimicrobial period. These demonstrating blood analysis, patient benefits provides are cost show demonstrate of alternatives. the able value savings and the impact, compared provider data XX% XX% retrospective A consistently BCID clinical stewardship system XX-month culture for impact to to that broader ePlex for pathogen and is we level. clinical at conducting also our own reviews coverage of the hospital competitive
ePlex CMS participation antimicrobial to acceptance and by to the and actionable infections coverage solution and perhaps develop only BCID by that Another with contributing and guidelines their in of and an therapy, integrated comments the the required regulations is more templated aligned delivering to pharmacy immediately use practice offers results goals formularies. U.S. programs. these of address decrease antibiotic reduce more programs that which helps pathogen to specifically factor module new make caused resistance ability importantly are unique designed ID is alignment is resistance gene market microbial appropriate ePlex spread These the conditions our of multidrug of organisms. BCID resistant diagnostic local drive to directly hospitals implement broad stewardship panel with
higher our One antibiotic make We diagnostic ePlex had marketing BCID. Overall, presented regarding based of last the favored pharmacists blinded Several panels. both panel. ID awareness to during continues and leaders through versus results. key study and rapid selection Week The comparison test grow management patient decisions impact two of month, highlighted well which BCID competing gram-positive opinion the in benefits organisms for the scored globally. presented gram-negative efforts BCID laboratory ePlex on as our both support as disease were infectious studies
highlighting tests that achieve with Another a by inclusivity. comparable Northeast its ePlex academic early eliminating potential are collectively numerous significantly from the to diagnostic in laboratory director blood other medical workflows major center culture shared streamline required to BCID, her experience
a investigators our gram-positive with to leading before study of partner our major fungal cancer and are in live three us studies study and U.S. gram-negative for all enable in with Clinical and participated papers clinical to center the who including fungal the publication expect pleased summarizing and under some is journal institutions announce submitted the These recently BCID we went year. studies country, that we the for and to planned Microbiology future Finally, panels. review a in manuscript of be of the the end review
like on GenMark’s landscape I’d comment now and briefly the to reimbursement status. recent to updates
As administrative late to coverage most patients, in in outpatient contractors used year year, and the coverage a reminder, certain panels earlier which Medicare large local this testing sales restrict determinations, last of respiratory commonly setting.
elderly our impact for value high cases, our these access While a the have immunocompromised. certain customers had coverage risk on policies in among more the reduced patients, such business date, restrictive to only in test high have resulted confusion they clinical and modest a to RP and as
with to to patients collaboratively provide clarity that XXXX RP we been about ePlex assigned by share and end, this, pleased various to lab ensuring reimbursed would stakeholders Laboratory by recommendation during in stakeholders, the in this code published for the AMA code for or season. worked to And and has be fee recently PLA covered Panel are for clinical the CPT to ePlex flu the their draft schedule. a to how Proprietary respiratory RP we’re season, that XXXX, response will paid PLA the RP In be access Analysis preliminary XXXX that ePlex be to relevant optimistic PLA relevant Based discussion code we existing model. Medicaid CMS With to a code with respiratory the ePlex on Medicare geographic testing. the and crosswalk for upcoming our panel
and AMA, at constructively this have those on to grateful with the important are who us We MolDX CMS topic. engaged
market. and the differentiated as XXXX, gain. menu continues company market the With high advancement summary, operational along continue as of efficiency platform for commercial of is to our by quality the we highly ongoing our to and attractive encouraged rapidly care. and multiplexing in In quarter patient that I’m molecular strong also momentum this a enter R&D in delivering final the ePlex priorities increasingly our and team testing a recognized the very drive with best-in-class performance I’m center very that consistent growth being execution our confident will superior growing
I’ll operational update. for point, to Scott his this At call the turn Scott? over
